Journal ArticleDOI
Priorities in Parkinson's disease research
Wassilios G. Meissner,Wassilios G. Meissner,Mark Frasier,Thomas Gasser,Christopher G. Goetz,Andres M. Lozano,Paola Piccini,Jose A. Obeso,Olivier Rascol,Anthony H.V. Schapira,Valerie Voon,David M. Weiner,François Tison,François Tison,Erwan Bezard +14 more
Reads0
Chats0
TLDR
This Review describes the most promising biological targets and therapeutic agents that are currently being assessed to address treatment goals of Parkinson's disease.Abstract:
The loss of dopaminergic neurons in the substantia nigra pars compacta leads to the characteristic motor symptoms of Parkinson's disease: bradykinesia, rigidity and resting tremors. Although these symptoms can be improved using currently available dopamine replacement strategies, there is still a need to improve current strategies of treating these symptoms, together with a need to alleviate non-motor symptoms of the disease. Moreover, treatments that provide neuroprotection and/or disease-modifying effects remain an urgent unmet clinical need. This Review describes the most promising biological targets and therapeutic agents that are currently being assessed to address these treatment goals. Progress will rely on understanding genetic mutations or susceptibility factors that lead to Parkinson's disease, better translation between preclinical animal models and clinical research, and improving the design of future clinical trials.read more
Citations
More filters
Journal ArticleDOI
Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.
Frank Schneider,Lavi Erisson,Hooman Beygi,Margaret Bradbury,Orit Cohen-Barak,Igor D. Grachev,Serge Guzy,Pippa S. Loupe,Micha Levi,Mirna McDonald,Juha-Matti Savola,Spyros Papapetropoulos,William Tracewell,Maria Velinova,Ofer Spiegelstein +14 more
TL;DR: The present study investigated the peripheral pharmacokinetics (PK), metabolism and safety of SD‐1077, a selectively deuterated precursor of dopamine structurally related to L‐3,4‐dihydroxyphenylalanine that is under development for treatment of motor symptoms of Parkinson's disease.
Book ChapterDOI
Endosomal sorting pathways in the pathogenesis of Parkinson's disease.
TL;DR: The known functions of PD-associated gene products, the impact of disease-linked mutations, and the emerging functional interactions between these proteins points to endosomal sorting pathways as a key point of convergence in the pathogenesis of PD.
Journal ArticleDOI
9-Methyl-β-carboline-induced cognitive enhancement is associated with elevated hippocampal dopamine levels and dendritic and synaptic proliferation.
Michael Gruss,Dorothea Appenroth,Armin Flubacher,Armin Flubacher,Christoph Enzensperger,Jörg Bock,Christian Fleck,Gabriele Gille,Katharina Braun +8 more
TL;DR: In this paper, the effect of 9-methyl-β-carboline (9-me-BC) on dopaminergic neurons in primary mesencephalic cultures was discovered.
Patent
Drug delivery methods and systems
Zita S. Netzel,Gary Stacey,Norman Alexander David,Huang Congyi,Frearson Timothy Charles,Charles Frazer Kilby,Patrick H. Ruane,Alan Joel Levy,Kevin W. Gelston,Jennifer A. Darmour,Jenny E. Hapgood,David Evans Roth,Ronald A. Overbeck,Ling-Kang Tong +13 more
TL;DR: In this paper, a two-part bioactive agent delivery system is described, which includes a disposable part comprising an agent reservoir, a bolus chamber, and a reusable part including a valve driver, a power source and control electronics, the control electronics being adapted to control the valve driver to actuate the valve to deliver bioactive agents from the agent reservoir to the agent outlet.
Proceedings ArticleDOI
Parkinson's disease detection using olfactory loss and REM sleep disorder features.
TL;DR: Olfactory loss feature from 40-item University of Pennsylvania Smell Identification Test and Sleep behavior disorder feature from Rapid eye movement sleep Behavior Disorder Screening Questionnaire, obtained from the Parkinson's Progression Marker's Initiative database, are used to develop automated diagnostic models using Support Vector Machine (SVM) and classification tree methods.
References
More filters
Journal ArticleDOI
Parkinson’s disease: clinical features and diagnosis
TL;DR: A thorough understanding of the broad spectrum of clinical manifestations of PD is essential to the proper diagnosis of the disease and genetic mutations or variants, neuroimaging abnormalities and other tests are potential biomarkers that may improve diagnosis and allow the identification of persons at risk.
Journal ArticleDOI
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium
Ian G. McKeith,Ian G. McKeith,Dennis W. Dickson,James Lowe,Murat Emre,John T. O'Brien,Howard Feldman,Jeffrey L. Cummings,John E. Duda,Carol F. Lippa,Elaine K. Perry,Dag Aarsland,Hiroyuki Arai,Clive Ballard,B. F. Boeve,David J. Burn,Durval C. Costa,T. Del Ser,Bruno Dubois,Douglas Galasko,Serge Gauthier,Christopher G. Goetz,Estrella Gómez-Tortosa,Glenda M. Halliday,L. A. Hansen,John Hardy,Takeshi Iwatsubo,Raj N. Kalaria,Daniel I. Kaufer,Rose Anne Kenny,Amos D. Korczyn,Kenji Kosaka,Virginia M.-Y. Lee,Andrew J. Lees,Irene Litvan,Elisabet Londos,Oscar L. Lopez,Satoshi Minoshima,Yoshikuni Mizuno,José Antonio Molina,Elizabeta B. Mukaetova-Ladinska,Florence Pasquier,Robert H. Perry,Jörg B. Schulz,John Q. Trojanowski,Masahito Yamada +45 more
TL;DR: The dementia with Lewy bodies (DLB) Consortium has revised criteria for the clinical and pathologic diagnosis of DLB incorporating new information about the core clinical features and suggesting improved methods to assess them as mentioned in this paper.
Journal ArticleDOI
α-Synuclein Locus Triplication Causes Parkinson's Disease
Andrew B. Singleton,Matthew J. Farrer,Joshua C. Johnson,Amanda Singleton,Stephen Hague,Jennifer M. Kachergus,Mary M. Hulihan,Terhi Peuralinna,Amalia Dutra,Robert L. Nussbaum,Sarah Lincoln,Anthony Crawley,Melissa Hanson,Demetrius M. Maraganore,Charles H. Adler,Mark R. Cookson,Manfred D. Muenter,Melisa J. Baptista,David Miller,J. Blancato,John Hardy,Katrina Gwinn-Hardy +21 more
TL;DR: In this article, the α-synuclein was identified as the major component of Lewy bodies, the pathological hallmark of Parkinson's disease, and of glial cell cytoplasmic inclusions.
Related Papers (5)
Mutation in the α-synuclein gene identified in families with Parkinson's disease
Mihael H. Polymeropoulos,Christian Lavedan,Elisabeth Leroy,Susan E. Ide,Anindya Dehejia,Amalia Dutra,Brian L. Pike,Holly Root,Jeffrey Rubenstein,Rebecca Boyer,Edward S. Stenroos,Settara C. Chandrasekharappa,Aglaia Athanassiadou,Theodore Papapetropoulos,William G. Johnson,Alice Lazzarini,Roger C. Duvoisin,Giuseppe Di Iorio,Lawrence I. Golbe,Robert L. Nussbaum +19 more